Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.53 -0.12 (-7.26%)
As of: Oct 1, 2026 · 3:59 PM EDT

Transcode Therapeutics (RNAZ) Preferred Stock Liabilities (2025 - 2026)

Updated

Transcode Therapeutics (RNAZ) recorded Preferred Stock Liabilities of $166.05 million in Q2 2026, up 15.9% from the prior quarter.

Analysis

Transcode Therapeutics (RNAZ) Preferred Stock Liabilities (2025 - 2026) Analysis & Trends

At the end of FY2025, Transcode Therapeutics reported Preferred Stock Liabilities of $141.54 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Transcode Therapeutics 1.70 Mn 1.70 Mn - 166.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 166.05 Mn
Mar 31, 2026 143.27 Mn
Dec 31, 2025 141.54 Mn
API Access

Transcode Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=RNAZ&period=max&api_key=YOUR_API_KEY